Cellectar Biosciences, Inc. develops targeted cancer therapies utilizing its proprietary PLE platform, which enables the selective delivery of therapeutic agents directly to cancer cells. The company focuses on advanced cancers with significant unmet medical needs, aiming to improve patient outcomes by extending survival and enhancing quality of life. Cellectar's approach supports the development of multiple drug classes, emphasizing precision in treatment while minimizing harm to healthy tissue.
